Cancer Types Spotlight
- Bladder
- Bone
- Breast
- CNS/Brain
- Colon and Rectum
- Endocrine System
- Esophagus
- GYN (Non-Ovary)
- GYN (Ovary)
- Head and Neck
- HIV-Related Cancers
- Hodgkin's Lymphoma
- Kidney (Renal Cell)
- Leukemia
- Liver and Bile Duct
- Lung
- Multiple Myeloma
- Myelodysplastic Syndrome
- Myeloproliferative Diseases
- Non-Hodgkin's Lymphoma
- Pancreas
- Pediatric Cancers
- Prostate
- Rare Cancers
- Skin (Melanoma)
- Skin (Non-Melanoma)
- Soft-Tissue Sarcoma
- Stomach
- Testicle
Anastrozole's Superiority in Preventing Recurrence Confirmed In 100-Month ATAC Follow-Up
Anastrozole's Superiority Shown in ATAC Follow-up
B. Jancin
20071120
2007 Dec 20
Elsevier Global Medical News
Anastrozole's Superiority in Preventing Recurrence Confirmed In 100-Month ATAC Follow-Up
Elsevier Global Medical News. 2007 Dec 20, B. Jancin
SAN ANTONIO (EGMN) - The efficacy of the aromatase inhibitor anastrozole for prevention of breast cancer recurrence persists for years after treatment completion - but the side effects do not, according to the 100-month follow-up analysis of the landmark Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. "This is the first demonstration of a carryover effect for an aromatase inhibitor," Dr. John F. Forbes said in presenting the median 100-month ATAC data at the annual San Antonio Breast Cancer...
